Arp2/3 Inhibition Synergizes With PARP Inhibitors by Impairing Homologous Recombination in Gastric Cancer Cells
Frontiers in Bioscience-Landmark · 2026
DOI: 10.31083/fbl51619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Wenlong Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Protein Structure and Function, Institute of Medicine and Pharmacy, Qiqihar Medical University, 161006 Qiqihar, Heilongjiang, China. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Stomach Neoplasms, Actin-Related Protein 2-3 Complex, Homologous Recombination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Provincial Natural Science Foundation of China, Qiqihar Medical Institute Foundation, Education Department Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Background:Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown limited efficacy in gastric cancer, primarily due to the rarity of inherent homologous recombination (HR) deficiency. The nuclear Arp2/3 complex was recently implicated in DNA double-strand break repair via HR. Here, we investigate whether pharmacological inhibition of Arp2/3 can induce a functional HR-deficient state to synergize with PARPi in gastric cancer cells.Methods:HR repair efficiency was assessed using a direct repeat green fluorescent protein (DR-GFP) reporter assay in HEK-293T cells following Arp2/3 inhibition with CK666, siRNA-mediated knockdown, or CRISPR/Cas9-mediated knockout of ACTR2/ACTR3. HGC-27 and AGS gastric cancer cells were treated with CK666 alone and in combination with olaparib or niraparib. Cell viability and synergy were evaluated by Cell Counting Kit-8 (CCK-8) and clonogenic assays (n = 3 independent experiments). DNA damage and apoptosis were assessed by immunofluorescence for gamma H2A histone family member X (γH2AX) foci (≥100 cells per condition) and Western blot analysis for cleaved PARP.Results:Arp2/3 inhibition with CK666 significantly impaired HR repair efficiency in the DR-GFP assay (p < 0.01). This effect was recapitulated by genetic knockdown or knockout of ACTR2/ACTR3. CK666 alone exerted minimal cytotoxicity, but synergized with both olaparib and niraparib to suppress proliferation (Combination Index
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Protein Structure and Function, Institute of Medicine and Pharmacy, Qiqihar Medical University, 161006 Qiqihar, Heilongjiang, China.
- School of Medical Technology, Qiqihar Medical University, 161006 Qiqihar, Heilongjiang, China.
- School of Basic Medical Sciences, Qiqihar Medical University, 161006 Qiqihar, Heilongjiang, China.
- Department of Gastroenterology, The First Hospital of Qiqihar, 161005 Qiqihar, Heilongjiang, China.
Förderung
- Heilongjiang Provincial Natural Science Foundation of China
- Qiqihar Medical Institute Foundation
- Education Department Foundation of Heilongjiang Province
- Construction Project of Dominant Characteristic Disciplines of Qiqihar Medical University
Zitieren
APA
Li, W., Pei, X., Li, Y., Lu, Y., Hong, X., Sui, M., Li, Q., Sun, X., Wang, J., Zhang, E., Liu, Y., Wang, T., Xu, J., & Deng, Z. (2026). Arp2/3 Inhibition Synergizes With PARP Inhibitors by Impairing Homologous Recombination in Gastric Cancer Cells. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl51619
Vancouver
Li W, Pei X, Li Y, Lu Y, Hong X, Sui M, et al. Arp2/3 Inhibition Synergizes With PARP Inhibitors by Impairing Homologous Recombination in Gastric Cancer Cells. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl51619
BibTeX
@article{Li2026,
author = {Li, Wenlong and Pei, Xinyue and Li, Yongpei and Lu, Yanji and Hong, Xian and Sui, Ming and Li, Qiang and Sun, Xueying and Wang, Jingqiu and Zhang, Enming and Liu, Yihan and Wang, Tao and Xu, Jing and Deng, Zhihui},
title = {Arp2/3 Inhibition Synergizes With PARP Inhibitors by Impairing Homologous Recombination in Gastric Cancer Cells},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
doi = {10.31083/fbl51619}
}
EUVIMED